- Report
- September 2024
- 100 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- December 2024
- 144 Pages
Global
From €13647EUR$14,995USD£11,699GBP
- Report
- September 2018
- 174 Pages
Global
From €1251EUR$1,375USD£1,073GBP
€2503EUR$2,750USD£2,146GBP
- Report
- March 2024
- 397 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €455EUR$500USD£390GBP
Aristada is a brand of long-acting injectable antipsychotic medications used to treat schizophrenia. It is a once-monthly injection that helps to reduce symptoms of schizophrenia, such as hallucinations, delusions, and disorganized thinking. Aristada is a combination of aripiprazole and paliperidone palmitate, two drugs that work together to reduce symptoms of schizophrenia. Aristada is designed to provide a steady, consistent level of medication in the body over a longer period of time than other antipsychotic medications. This helps to reduce the risk of relapse and improve overall outcomes for people with schizophrenia.
Companies in the Aristada market include Alkermes, Otsuka Pharmaceuticals, and Lundbeck. Show Less Read more